Sonoma enters exclusive South Korea distribution deal with Daewoong for Primocyn

Sonoma Pharmaceuticals, Inc.

Exclusive distribution agreement effective Jan 26, 2023 for Primocyn Skin Solution (Microcyn technology) in South Korea.
Initial term of two years, automatically renewing for two-year periods unless terminated.
Daewoong responsible for obtaining marketing authorization and all regulatory clearances in the territory.
Minimum purchase thresholds (redacted) required to maintain exclusivity beyond second year; initial fee also redacted.
Sonoma to provide registration dossier within 90 days; Daewoong to apply for marketing authorization.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Sonoma Pharmaceuticals, Inc. entered into Exclusive Distribution Agreement with Daewoong Pharmaceutical Co., Ltd. valued at Exclusive distribution agreement for Primocyn Skin Solution products containing Microcyn technology (effective 2023-01-26).

Action: entry
Agreement: license
Counterparty: Daewoong Pharmaceutical Co., Ltd.
Value: Exclusive distribution agreement for Primocyn Skin Solution products containing Microcyn technology
Effective: 2023-01-26

Exact text from the filing

Effective January 26, 2023, we entered into an exclusive distribution agreement with Daewoong Pharmaceutical Co., Ltd. for the marketing and distribution of Primocyn TM Skin Solution products, containing our Microcyn® technology, in South Korea.

View on SEC.gov

Browse all material agreements →

Sonoma Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-23-000420

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.